FreeCME

2nd Annual Symposium on Current Strategies in the Diagnosis and Treatment of Multiple Sclerosis

This webcast is jointly provided by A. Webb Roberts Center for CME of Baylor Health Care System and MedNet.

For more information visit: www.mednetus.net

Grantors:

Biogen/IDEC

Scroll to the Bottom of this Information to Begin this Course

Target Audience

These webcasts are directed primarily to neurologists, radiologists, physician assistants, nurse practitioners, pharmacists, registered nurses, and clinicians involved in the management of patients with multiple sclerosis (MS). No specific skill or knowledge other than a basic training in neurology is required for successful participation in this activity. 

Program Overview

These webcasts are intended to provide paradigm shift in the treatment options for MS. The format will include didactic lectures from known thought leaders, question and answer sessions, case report presentation and ample opportunity for participant interaction with faculty. This enduring online activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

This program consists of 4 continuing education activites.

Click the links below to review the activity launch pages containing full disclosure information.

 

Module 1 — Victor M. Rivera, MD & Benjamin M. Greenberg, MD — 1.0 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the immunological basis and the mechanisms of action and its relevance to treatment of MS
  • Provide updated strategies for accurate diagnosis which will enable appropriate treatment of patients with MS

 

Module 2 — Darin T. Okuda, MD & Victor M. Rivera, MD — 1.25 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the role of high-field MRI in monitoring disease activity in patients with MS with an emphasis on use and misuse
  • Discuss the disease-modifying therapies for MS and the criteria for selection of patients

 

Module 3 — George J. Hutton, MD & John W. Lindsey, MD — 1.75 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the disease-modifying therapies for MS and the criteria for initiating and switching disease-modifying therapies
  • Identify and select novel therapeutic options with mononclonal antibodies for MS
  • Assess the pregnancy issues in patients with MS

 

Module 4 — Francisco Perez, PhD & Rosa A. Tang, MD — 1.0 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify cognition, depression and other psychological issues in patients with MS
  • Evaluate the disabling symptoms of Uhthoff’s phenomenon in patients with MS